GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NRX Pharmaceuticals Inc (STU:B1Q) » Definitions » Short Percentage of Float

NRX Pharmaceuticals (STU:B1Q) Short Percentage of Float


View and export this data going back to 2020. Start your Free Trial

What is NRX Pharmaceuticals Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of NRX Pharmaceuticals's Short Percentage of Float

For the Biotechnology subindustry, NRX Pharmaceuticals's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NRX Pharmaceuticals's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NRX Pharmaceuticals's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where NRX Pharmaceuticals's Short Percentage of Float falls into.


NRX Pharmaceuticals (STU:B1Q) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NRX Pharmaceuticals Inc (STU:B1Q) » Definitions » Short Percentage of Float
Comparable Companies
VIRX PIRS ABIO CADL MRKR ENLV NCNA ORGS SRNEQ MTEM OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
NRXP:USA
Address
1201 Orange Street, Suite 600, Wilmington, DE, USA, 19801
Website
https://nrxpharma.com
NRX Pharmaceuticals Inc is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. It is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behaviour.

NRX Pharmaceuticals (STU:B1Q) Headlines

No Headlines